ORCID Profile
0000-0002-7939-8351
Current Organisations
University College Hospital
,
Royal Free London NHS Foundation Trust
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 12-2019
DOI: 10.1016/J.JNS.2019.116456
Abstract: To evaluate an updated algorithm in the detection of urinary tract infection (UTI) prior to high-dose corticosteroid treatment in acute relapses in multiple sclerosis (MS). This updated algorithm aimed to decrease the unnecessary use of antibiotics, whilst maintaining accuracy and safety. Prospective cohort study of 471 consecutive patients with MS relapses in a hospital-based outpatient acute relapse clinic. 172 patients met exclusion criteria, leaving 299 patients for analysis. Patients underwent urine dipstick and were treated for UTI if 2 or more of: nitrites, leukocyte esterase and cloudy urine were positive. Patients with confirmed acute MS relapse were treated with high dose intravenous or oral methylprednisolone. Significant bacteriuria (>10 With an improved specificity, this updated algorithm addresses previous issues concerning the unnecessary prescription of antibiotics, whilst improving accuracy and maintaining safety.
Publisher: Mark Allen Group
Date: 02-02-2019
DOI: 10.12968/BJNN.2019.15.1.20
Abstract: Multiple sclerosis (MS) can result in multi-level uro-neurological dysfunction that significantly increases the risk of urinary tract infections (UTIs). UTIs in patients with MS can lead to significant patient morbidity and cost to the National Health Service (NHS). Data collected from the NHS clinical commissioning groups in 2012/2013, and again in 2016/2017, revealed that UTI remains the most common cause of non-elective hospital admission in patients with MS, and that the overall cost of such admissions continued to rise across this period. In order to address this burgeoning problem, we used the evidence-based co-design methodology to collaborate with patients, their families and clinical staff to create a novel and innovative, patient-centred model called NeuroResponse®. We present the multi-faceted NeuroResponse® model and the results of the pilot study in the London Borough of Camden.
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for bernadette porter.